4D Molecular Therapeutics (FDMT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $36.00 price target on the stock.
4D Molecular Therapeutics (FDMT) had its price target raised by Royal Bank Of Canada from $32.00 to $35.00. They now have an "outperform" rating on the stock.
4D Molecular Therapeutics (FDMT) had its "buy" rating reaffirmed by Chardan Capital. They now have a $26.00 price target on the stock.
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones